Obesity and mental illness: Implications for cognitive functioning

Advances in Therapy

Volumn 30, Issue 6, 2013, Pages 577-588

  McIntyre, Roger S ^a,b,c   Cha, Danielle S ^b,c   Jerrell, Jeanette M ^d   Soczynska, Joanna K ^b,c   Woldeyohannes, Hanna O ^c   Taylor, Valerie ^a   Kaidanovich Beilin, Oksana ^c,e   Alsuwaidan, Mohammad ^a,c   Ahmed, Ameena T ^f,g  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e MOUNT SINAI HOSPITAL   (Canada)

^f KAISER PERMANENTE MEDICAL CENTER   (United States)

^g DIVISION OF RESEARCH   (United States)

Author keywords

Cognition; Dementia; Mental illness; Mood disorder; Neuropsychiatric disorders; Obesity; Psychiatry

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CYTOKINE; GLUCOSE; VALPROIC ACID;

ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; COGNITION; COGNITIVE DEFECT; DEMENTIA; EATING DISORDER; FRACTIONAL ANISOTROPY; GLUCOSE TRANSPORT; HUMAN; HYPERCORTISOLISM; MAJOR DEPRESSION; MENTAL DISEASE; NEUROTOXICITY; OBESITY; OXIDATIVE STRESS; PHENOTYPE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

COGNITION DISORDERS; HUMANS; MENTAL DISORDERS; OBESITY;

EID: 84880256533     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0040-5     Document Type: Review

References (99)

1. Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature. 2011;475:27-30.
2. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21:169-84.
3. Rossler W. Stress, burnout, and job dissatisfaction in mental health workers. Eur Arch Psychiatry Clin Neurosci. 2012;262(Suppl 2):S65-9.
4. Alonso J, Vilagut G, Chatterji S, et al. Including information about co-morbidity in estimates of disease burden: results from the World Health Organization World Mental Health Surveys. Psychol Med. 2011;41:873-86.
5. Williams JM, Healy H, Eade J, et al. Mood, eating behaviour and attention. Psychol Med. 2002;32:469-81.
6. Delgado-Rico E, Rio-Valle JS, Gonzalez-Jimenez E, Campoy C, Verdejo-Garcia A. BMI predicts emotion-driven impulsivity and cognitive inflexibility in adolescents with excess weight. Obesity (Silver Spring). 2012;20:1604-10.
7. Joseph RJ, Alonso-Alonso M, Bond DS, Pascual-Leone A, Blackburn GL. The neurocognitive connection between physical activity and eating behaviour. Obes Rev. 2011;12:800-12.
8. Hendrickx H, McEwen BS, Ouderaa F. Metabolism, mood and cognition in aging: the importance of lifestyle and dietary intervention. Neurobiol Aging. 2005;26(Suppl 1):1-5.
9. Chang CK, Hayes RD, Perera G, et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS ONE. 2011;6:e19590.
10. Megna JL, Schwartz TL, Siddiqui UA, Herrera RM. Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions. Ann Clin Psychiatry. 2011;23:131-40.
11. McIntyre RS. Managing weight gain in patients with severe mental illness. J Clin Psychiatry. 2009;70:e23.
12. Ravaldi C, Barboni E, Lai M, Rotella CM, Vannacci A, Ricca V. Obesity and mood disorders: the complex problem of insight. J Clin Psychiatry. 2005;66:265.
13. Yim CY, Soczynska JK, Kennedy SH, Woldeyohannes HO, Brietzke E, McIntyre RS. The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur Psychiatry. 2012;27:223-8.
14. Gurpegui M, Martinez-Ortega JM, Gutierrez-Rojas L, Rivero J, Rojas C, Jurado D. Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:169-75.
15. Galioto R, Spitznagel MB, Strain G, et al. Cognitive function in morbidly obese individuals with and without binge eating disorder. Compr Psychiatry. 2012;53:490-5.
16. Ramacciotti CE, Coli E, Bondi E, Burgalassi A, Massimetti G, Dell'Osso L. Shared psychopathology in obese subjects with and without binge-eating disorder. Int J Eat Disord. 2008;41:643-9.
17. Cournot M, Marquie JC, Ansiau D, et al. Relation between body mass index and cognitive function in healthy middle-aged men and women. Neurology. 2006;67:1208-14.
18. Grosshans M, Loeber S, Kiefer F. Implications from addiction research towards the understanding and treatment of obesity. Addict Biol. 2011;16:189-98.
19. Laitala VS, Kaprio J, Koskenvuo M, Raiha I, Rinne JO, Silventoinen K. Association and causal relationship of midlife obesity and related metabolic disorders with old age cognition. Curr Alzheimer Res. 2011;8:699-706.
20. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. 2000;23:542-9.
21. Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord. 2003;27:260-8.
22. Naderali EK, Ratcliffe SH, Dale MC. Obesity and Alzheimer's disease: a link between body weight and cognitive function in old age. Am J Alzheimer Dis Other Demen. 2009;24:445-9.
23. Yau PL, Castro Bs MG, Tagani A, Tsui WH, Convit A. Obesity and metabolic syndrome and functional and structural brain impairments in adolescence. Pediatrics. 2012;130:e856-64.
24. Cserjesi R, Luminet O, Poncelet AS, Lenard L. Altered executive function in obesity: exploration of the role of affective states on cognitive abilities. Appetite. 2009;52:535-9.
25. Singh-Manoux A, Czernichow S, Elbaz A, et al. Obesity phenotypes in midlife and cognition in early old age: the Whitehall II cohort study. Neurology. 2012;79:755-62.
26. Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008;71:1057-64.
27. Kullmann S, Heni M, Veit R, et al. The obese brain: association of body mass index and insulin sensitivity with resting state network functional connectivity. Hum Brain Mapp. 2012;33:1052-61.
28. Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005;62:1556-60.
29. Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med. 2003;163:1524-8.
30. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry. 2003;54:317-29.
31. Reus VI, Wolkowitz OM. Antiglucocorticoid drugs in the treatment of depression. Expert Opin Investig Drugs. 2001;10:1789-96.
32. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ. 2005;330:1360.
33. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3:169-78.
34. Gustafson DR. Adiposity and cognitive decline: underlying mechanisms. J Alzheimers Dis. 2012;30(Suppl 2):S97-112.
35. Stanley SH, Laugharne JD. Obesity, cardiovascular disease and type 2 diabetes in people with a mental illness: a need for primary health care. Aust J Prim Health. 2012;18:258-64.
36. Kanaya AM, Lindquist K, Harris TB, et al. Total and regional adiposity and cognitive change in older adults: the health, aging and body composition (ABC) study. Arch Neurol. 2009;66:329-35.
37. Kerwin DR, Gaussoin SA, Chlebowski RT, et al. Interaction between body mass index and central adiposity and risk of incident cognitive impairment and dementia: results from the Women's Health Initiative Memory Study. J Am Geriatr Soc. 2011;59:107-12.
38. Bagger YZ, Tanko LB, Alexandersen P, Qin G, Christiansen C. The implications of body fat mass and fat distribution for cognitive function in elderly women. Obes Res. 2004;12:1519-26.
39. Richardson JT. Cognitive function in diabetes mellitus. Neurosci Biobehav Rev. 1990;14:385-8.
40. Zhu X, Wang X, Xiao J, et al. Evidence of a dissociation pattern in resting-state default mode network connectivity in first-episode, treatment-naive major depression patients. Biol Psychiatry. 2012;71:611-7.
41. Uddin LQ, Kelly AM, Biswal BB, Xavier CF, Milham MP. Functional connectivity of default mode network components: correlation, anticorrelation, and causality. Hum Brain Mapp. 2009;30:625-37.
42. Musen G, Jacobson AM, Bolo NR, et al. Resting-state brain functional connectivity is altered in type 2 diabetes. Diabetes. 2012;61:2375-9.
43. Volkow ND, Tomasi D, Wang GJ, et al. Positive emotionality is associated with baseline metabolism in orbitofrontal cortex and in regions of the default network. Mol Psychiatry. 2011;16:818-25.
44. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci USA. 2001;98:676-82.
45. Broyd SJ, Demanuele C, Debener S, Helps SK, James CJ, Sonuga-Barke EJ. Default-mode brain dysfunction in mental disorders: a systematic review. Neurosci Biobehav Rev. 2009;33:279-96.
46. Whitfield-Gabrieli S, Ford JM. Default mode network activity and connectivity in psychopathology. Annu Rev Clin Psychol. 2012;8:49-76.
47. Gusnard DA, Akbudak E, Shulman GL, Raichle ME. Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function. Proc Natl Acad Sci USA. 2001;98:4259-64.
48. Gilbert SJ, Spengler S, Simons JS, et al. Functional specialization within rostral prefrontal cortex (area 10): a meta-analysis. J Cogn Neurosci. 2006;18:932-48.
49. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709-17.
50. Garcia-Garcia I, Jurado MA, Garolera M, et al. Functional connectivity in obesity during reward processing. Neuroimage. 2012;66C:232-9.
51. Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci USA. 2003;100:253-8.
52. Masters BA, Shemer J, Judkins JH, Clarke DW, Le Roith D, Raizada MK. Insulin receptors and insulin action in dissociated brain cells. Brain Res. 1987;417:247-56.
53. Shapiro E, Brown SD, Saltiel AR, Schwartz JH. Short-term action of insulin on Aplysia neurons: generation of a possible novel modulator of ion channels. J Neurobiol. 1991;22:55-62.
54. Shibata S, Liou SY, Ueki S, Oomura Y. Inhibitory action of insulin on suprachiasmatic nucleus neurons in rat hypothalamic slice preparations. Physiol Behav. 1986;36:79-81.
55. McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci. 1999;22:105-22.
56. McEwen BS, Magarinos AM, Reagan LP. Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes. J Psychosom Res. 2002;53:883-90.
57. Magarinos AM, McEwen BS. Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress. Proc Natl Acad Sci USA. 2000;97:11056-61.
58. Reagan LP, Gorovits N, Hoskin EK, et al. Localization and regulation of GLUTx1 glucose transporter in the hippocampus of streptozotocin diabetic rats. Proc Natl Acad Sci USA. 2001;98:2820-5.
59. McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain: implications for cognition and aging. Neurology. 1997;48(5 Suppl 7):S8-15.
60. Baydas G, Nedzvetskii VS, Nerush PA, Kirichenko SV, Yoldas T. Altered expression of NCAM in hippocampus and cortex may underlie memory and learning deficits in rats with streptozotocin-induced diabetes melitus. Life Sci. 2003;72:1907-16.
61. Greenwood CE, Winocur G. Glucose treatment reduces memory deficits in young adult rats fed high-fat diets. Neurobiol Learn Mem. 2001;75:179-89.
62. Rush AJ, Giles DE, Schlesser MA, et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry. 1996;57:470-84.
63. Mire-Sluis AR, Padilla A, Das RG. Biological standardization of cytokines and growth factors. Dev Biol Stand. 1999;97:171-6.
64. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol. 2011;14:997-1012.
65. Drexhage RC, Knijff EM, Padmos RC, et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother. 2010;10:59-76.
66. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171-86.
67. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446-57.
68. Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15:199-226.
69. Soczynska JK, Kennedy SH, Woldeyohannes HO, et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med. 2011;13:93-116.
70. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58:445-52.
71. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry. 2009;66:407-14.
72. Bob P, Raboch J, Maes M, et al. Depression, traumatic stress and interleukin-6. J Affect Disord. 2010;120:231-4.
73. Yoon DH, Choi SH, Yu JH, Ha JH, Ryu SH, Park DH. The relationship between visceral adiposity and cognitive performance in older adults. Age Ageing. 2012;41:456-61.
74. Andreazza AC, Kauer-Sant'anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord. 2008;111:135-44.
75. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35:804-17.
76. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 2003;8:365-70.
77. Chico L, Simoncini C, Gerfo AL, et al. Oxidative stress and APO E polymorphysms in Alzheimer's disease and in mild cognitive impairment. Free Radic Res. 2013. doi: 10.3109/10715762.2013.804622
78. Vieta E, Popovic D, Rosa AR, et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. Eur Psychiatry. 2013;28:21-9.
79. Selek S, Savas HA, Gergerlioglu HS, Bulbul F, Uz E, Yumru M. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord. 2008;107:89-94.
80. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol. 2004;19:89-95.
81. Andreazza AC, Kapczinski F, Kauer-Sant'anna M, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci. 2009;34:263-71.
82. Dhabhar FS, Burke HM, et al. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J Psychiatr Res. 2009;43:962-9.
83. Jones A, McMillan MR, Jones RW, et al. Adiposity is associated with blunted cardiovascular, neuroendocrine and cognitive responses to acute mental stress. PLoS ONE. 2012;7:e39143.
84. Bray GA. Risks of obesity. Endocrinol Metab Clin North Am. 2003;32:787-804, viii.
85. McElroy S, Allison D, Bray G. Obesity and mental disorders. New York: Taylor & Francis; 2006.
86. Henderson DC. Managing weight gain and metabolic issues in patients treated with atypical antipsychotics. J Clin Psychiatry. 2008;69:e04.
87. Kim B, Kim SJ, Son JI, Joo YH. Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord. 2008;105:45-52.
88. Kenna HA, Jiang B, Rasgon NL. Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment. Harv Rev Psychiatry. 2009;17(2):138-46.
89. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Kennedy SH. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord. 2003;5:28-35.
90. Garcia-Portilla MP, Saiz PA, Benabarre A, et al. The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 2008;106:197-201.
91. Wilson PW, Grundy SM. The metabolic syndrome: practical guide to origins and treatment: part I. Circulation. 2003;108:1422-4.
92. McIntyre RS, Alsuwaidan M, Goldstein BI, et al; Canadian Network for Mood and Anxiety Treatment (CANMAT) Task Force. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry. 2012;24:69-81.
93. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11:225-55.
94. Yatham LN, Kennedy SH, O'Donovan C, et al; Canadian Network for Mood and Anxiety Treatment Task Force. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005;7(Suppl 3):5-69.
95. Bond DJ, Hadjipavlou G, Lam RW, et al; Canadian Network for Mood and Anxiety Treatment Task Force. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry. 2012;24:23-37.
96. Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments (CANMAT). Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry. 2001;46(Suppl 1):5S-90S.
97. Taylor VH, McIntyre RS, Remington G, Levitan RD, Stonehocker B, Sharma AM. Beyond pharmacotherapy: understanding the links between obesity and chronic mental illness. Can J Psychiatry. 2012;57:5-12.
98. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as "Metabolic Syndrome Type II"? Ann Clin Psychiatry. 2007;19:257-64.
99. Morrato EH, Druss B, Hartung DM, et al. Metabolic testing rates in 3 state medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry. 2010;67:17-24.